(NASDAQ: QNRX) Quoin Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.44%.
Quoin Pharmaceuticals's earnings in 2026 is -$18,665,315.On average, 8 Wall Street analysts forecast QNRX's earnings for 2026 to be -$458,046,741, with the lowest QNRX earnings forecast at -$543,532,022, and the highest QNRX earnings forecast at -$321,070,654. On average, 7 Wall Street analysts forecast QNRX's earnings for 2027 to be -$187,426,532, with the lowest QNRX earnings forecast at -$306,554,816, and the highest QNRX earnings forecast at -$141,713,944.
In 2028, QNRX is forecast to generate -$125,834,390 in earnings, with the lowest earnings forecast at -$153,621,852 and the highest earnings forecast at -$94,475,963.